# A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment

> **NCT03812835** · — · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Thrombosis, Deep Vein
- Pulmonary Embolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03812835
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-23
- **Primary completion:** 2023-08-23
- **Final completion:** 2023-08-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company decision to not conduct study and was cancelled prior to any enrollment.
- **Last updated:** 2021-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03812835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03812835, "A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03812835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*